Identification of Novel Signals Associated with US-FDA Approved Drugs (2013) Using Disproportionality Analysis.

Disproportionality analysis FAERS OpenVigil 2.1 Sensitivity analysis Signal detection US-FDA approved drugs

Journal

Current drug safety
ISSN: 2212-3911
Titre abrégé: Curr Drug Saf
Pays: United Arab Emirates
ID NLM: 101270895

Informations de publication

Date de publication:
21 Nov 2023
Historique:
received: 17 08 2023
revised: 19 09 2023
accepted: 22 09 2023
medline: 22 11 2023
pubmed: 22 11 2023
entrez: 22 11 2023
Statut: aheadofprint

Résumé

Drugs are related with various adverse drug reactions (ADRs), however, many unexpected ADRs of drugs are reported through post-marketing surveillance. The current study's goal is to uncover potential signals connected with FDA-approved medications in the United States (2013). Open Vigil 2.1-MedDRA-v24 (data 20004Q1-2021Q3) was used as a tool to query the FAERS data. To find possible signals, disproportionality measures such as Proportional Reporting Ratio (PRR 2) with associated Chi-square value, Reporting Odds Ratio (ROR 2) with 95% confidence interval, and case count (3) were calculated. A total of eight potential signals were identified with five drugs. Positive signals were found with pomalidomide, canagliflozin, dolutegravir sodium, macitentan and ibrutinib. However, further causality assessment is required to confirm the association of these drugs with identified potential signals.

Sections du résumé

BACKGROUND BACKGROUND
Drugs are related with various adverse drug reactions (ADRs), however, many unexpected ADRs of drugs are reported through post-marketing surveillance.
AIM OBJECTIVE
The current study's goal is to uncover potential signals connected with FDA-approved medications in the United States (2013).
METHODOLOGY METHODS
Open Vigil 2.1-MedDRA-v24 (data 20004Q1-2021Q3) was used as a tool to query the FAERS data. To find possible signals, disproportionality measures such as Proportional Reporting Ratio (PRR 2) with associated Chi-square value, Reporting Odds Ratio (ROR 2) with 95% confidence interval, and case count (3) were calculated.
RESULTS RESULTS
A total of eight potential signals were identified with five drugs. Positive signals were found with pomalidomide, canagliflozin, dolutegravir sodium, macitentan and ibrutinib.
CONCLUSION CONCLUSIONS
However, further causality assessment is required to confirm the association of these drugs with identified potential signals.

Identifiants

pubmed: 37990902
pii: CDS-EPUB-136197
doi: 10.2174/0115748863276447231108092936
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Auteurs

Sourabh Raghuvanshi (S)

Department of Clinical Research, Delhi Pharmaceutical Science and Research University (DPSRU), New Delhi 110017, India.

Mohammad Akhlaquer Rahman (MA)

Department of Pharmaceutics and Industrial Pharmacy, college of Pharmacy, Taif University, Taif-- 21944, Kingdom of Saudi Arabia.

Mahesh Kumar Posa (MK)

School of Pharmacy and Technology Management, SVKM'S NMIMS, Polepally SEZ, Jadcherla, Hyderabad, 509301, India.

Anoop Kumar (A)

Department of Pharmacology, Delhi Pharmaceutical Science and Research University (DPSRU), New Delhi 110017, India.

Classifications MeSH